TY - JOUR
T1 - Delayed inflammatory reactions to hyaluronic acid fillers
T2 - A literature review and proposed treatment algorithm
AU - Artzi, Ofir
AU - Cohen, Joel L.
AU - Dover, Jeffrey S.
AU - Suwanchinda, Atchima
AU - Pavicic, Tatjana
AU - Landau, Marina
AU - Goodman, Greg J.
AU - Ghannam, Sahar
AU - Al Niaimi, Firas
AU - van Loghem, Jani A.J.
AU - Goldie, Kate
AU - Sattler, Sonja
AU - Cassuto, Daniel
AU - Lim, Ting Song
AU - Wanitphakdeedecha, Rungsima
AU - Verner, Ines
AU - Fischer, Tanja C.
AU - Bucay, Vivian
AU - Sprecher, Eli
AU - Shalmon, Dana
N1 - Publisher Copyright:
© 2020 Artzi et al.
PY - 2020
Y1 - 2020
N2 - Background and Objectives: There is a wide diversity of opinions regarding the management of delayed inflammatory reactions (DIRs) secondary to hyaluronic acid (HA)-based fillers. The plethora of approaches has led the authors to conduct a review regarding management and treatment of DIRs as well as establish therapeutic guidelines for this purpose. Materials and Methods: A review of the literature was performed through databases such as PubMed using keywords including HA-fillers and complications, delayed HA filler sequelae and therapy, soft tissue and dermal filler reactions and management. Additionally, a survey comprised of questions regarding the management and treatment of DIRs was sent to 18 physicians highly experienced with soft-tissue filler injections in 10 countries. Their answers and recommendations were analyzed and debated amongst these panelists. Results: Sixteen panelists favored antibiotic therapy as first-line treatment for DIRs, specifically dual antibiotic therapy consisting of a fluoroquinolone along with a tetracycline or macrolide for a period of 3–6 weeks. The majority refrained from the use of intralesional (IL) or systemic steroids except in the case of disfiguring or recalcitrant reactions. IL hyaluronidase was recommended by 13 panelists; however, some preferred a watchful waiting approach for a period of 48 hours to 2 weeks prior to IL hyaluronidase, and in cases where antibiotics did not lead to improvement. Conclusion: A consensus was reached and summarized to propose a clear, easy-to-follow, stepwise algorithm for the treatment of DIRs.
AB - Background and Objectives: There is a wide diversity of opinions regarding the management of delayed inflammatory reactions (DIRs) secondary to hyaluronic acid (HA)-based fillers. The plethora of approaches has led the authors to conduct a review regarding management and treatment of DIRs as well as establish therapeutic guidelines for this purpose. Materials and Methods: A review of the literature was performed through databases such as PubMed using keywords including HA-fillers and complications, delayed HA filler sequelae and therapy, soft tissue and dermal filler reactions and management. Additionally, a survey comprised of questions regarding the management and treatment of DIRs was sent to 18 physicians highly experienced with soft-tissue filler injections in 10 countries. Their answers and recommendations were analyzed and debated amongst these panelists. Results: Sixteen panelists favored antibiotic therapy as first-line treatment for DIRs, specifically dual antibiotic therapy consisting of a fluoroquinolone along with a tetracycline or macrolide for a period of 3–6 weeks. The majority refrained from the use of intralesional (IL) or systemic steroids except in the case of disfiguring or recalcitrant reactions. IL hyaluronidase was recommended by 13 panelists; however, some preferred a watchful waiting approach for a period of 48 hours to 2 weeks prior to IL hyaluronidase, and in cases where antibiotics did not lead to improvement. Conclusion: A consensus was reached and summarized to propose a clear, easy-to-follow, stepwise algorithm for the treatment of DIRs.
KW - Cosmetic techniques
KW - Dermal fillers/adverse effects
KW - Hyaluronic acid/adverse effects
UR - http://www.scopus.com/inward/record.url?scp=85085349655&partnerID=8YFLogxK
U2 - 10.2147/CCID.S247171
DO - 10.2147/CCID.S247171
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:85085349655
SN - 1178-7015
VL - 13
SP - 371
EP - 378
JO - Clinical, Cosmetic and Investigational Dermatology
JF - Clinical, Cosmetic and Investigational Dermatology
ER -